Cargando…
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
BACKGROUND: Bispecific antibody has garnered considerable attention in the recent years due to its impressive preliminary efficacy in hematological malignancies. For solid tumors, however, the main hindrance is the suppressive tumor microenvironment, which effectively impedes the activation of infil...
Autores principales: | Huang, Po-Lin, Kan, Hung-Tsai, Hsu, Ching-Hsuan, Hsieh, Hsin-Ta, Cheng, Wan-Chien, Huang, Ren-Yeong, You, Jhong-Jhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210478/ https://www.ncbi.nlm.nih.gov/pubmed/37226226 http://dx.doi.org/10.1186/s12967-023-04193-5 |
Ejemplares similares
-
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023) -
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021) -
Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021) -
The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer
por: Xu, Naijin, et al.
Publicado: (2019) -
An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
por: Wei, Mulan, et al.
Publicado: (2018)